ClinicalTrials.gg
Not yet recruitingNCT07484399Updated Mar 20, 2026

Comparing Effects of HIIT and MICT on Functional Mobility, Muscle Strength, and Quality of Life in Diabetic Patients

An interventional study of High Intensity Interval Training and Moderate Intensity Continuous Training in Type 2 Diabetes Mellitus With Complication, sponsored by Riphah International University. Not yet recruiting. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Riphah International University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Diabetes Mellitus, Type 2 by Riphah International University — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Riphah International University.

Planned enrollment
18th of 19
28 · median 46
Started
2026
with 2 others
No phase
19 of 19
6 open now
Registered
17th of 19
by date

Among the 19 studies in Diabetes Mellitus, Type 2 by Riphah International University, this one is the 18th largest by planned enrollment, is one of 3 that started in 2026, is one of 19 with no phase, and was the 17th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 19 studies in Diabetes Mellitus, Type 2 by Riphah International University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Diabetes Mellitus, Type 2 by Riphah International University, or all of them as a file.
02

Study summary

To compare the effects of High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) on functional mobility, muscle strength, and quality of life in individuals with type-2-diabetes.

Read the detailed description

Comparing the effects of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) on functional mobility, muscle strength, and quality of life in diabetic patients is important due to the increasing burden of diabetes and its associated complications. Diabetes often leads to reduced physical function, muscle weakness, and poor quality of life. While both HIIT and MICT have demonstrated positive effects on health outcomes, it is not yet clear which exercise regimen offers superior benefits for improving mobility, strength, and overall well-being in diabetic individuals.

Diabetes often leads to reduced physical function, muscle weakness, and poor quality of life. While both HIIT and MICT have demonstrated positive effects on health outcomes, it is not yet clear which exercise regimen offers superior benefits for improving mobility, strength, and overall well-being in diabetic individuals. Understanding this can guide the development of more effective exercise protocols for diabetes management.

03

Conditions studied

  • Type 2 Diabetes Mellitus With Complication

Keywords

  • muscles weakness, disability, reduced quality of life,
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

:• Adults aging form 35 to 65.

  • Both male and female diabetic patients.
  • Individuals diagnosed with type 2 diabetes for at least five years.
  • Individuals able to participate in moderate to intense physical activity.

Exclusion criteria

Exclusion Criteria:

    • Individuals with significant orthopedic limitations.

      • Individuals with uncontrolled cardiovascular disease or musculoskeletal issues.
      • Individuals with incontinence issues during physical activity or inability to comply to study protocols
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Active comparator
    High Intensity Interval Training

    Warm-up: - 5 minutes of dynamic stretching.Exercise Intervals- 4 sets of 4 minutes high-intensity exercises (i.e, sprint intervals on a treadmill and squat jumping) - Intensity: Corresponding to perceived exertion rating (RPE) of 15-18 on the Borg 6-20 scale (32).Cool-down:- 3 minutes of active recovery intervals- Intensity: Rating of perceived exertion (RPE) 8 to 10.Schedule:- Frequency: 3 times per week- Duration: 12-week period- Total session duration: 30-32 minutesObjective:- Focus on maximizing cardiovascular and muscular adaptations through brief, intense activity bursts.

    Other: High Intensity Interval Training

  • Active comparator
    Moderate Intensity Continuous Training

    Warm-up:- 5 minutes of dynamic stretching.Continuous Exercise:- 40 minutes of moderate-intensity exercises (i.e., brisk walking on a treadmill) - Intensity: Perceived exertion rate of 11-13 on the Borg 6-20 scale (34).Cool-down: None (continuous without intervals)Schedule:- Frequency: 3 times per week- Duration: 12-week period- Total session duration: 45 minutesObjective:- Promote endurance and quality of life with a sustainable approach to improving overall physical endurance.

    Other: Moderate Intensity Continuous Training

Interventions

  • OtherHigh Intensity Interval Training

    3 session per week, 12 weeks sessions continued, each session had 4 sets of 4 minutes exercise with 3 min active rest inbetween routines. total 30 minutes per session, Sprinting and Jump squatting RPE 15-18

  • OtherModerate Intensity Continuous Training

    3 session per week, 12 weeks sessions continued, 40 minutes one single exercise regime with no intervals. Brisk Walking on Treadmill, RPE-11-13

06

What researchers measure

Primary outcomes

  1. TUG timed up go test

    Functional mobility is evaluated by the TUG test. The TUG test has revealed very high test-retest reliability among patients with diabetes, as shown by the ICC values from 0.93 to 0.99

    Time frame: baseline pre exam, 6th week of intervention, and 12th week

  2. Hand Grip Strength Test

    To assess the power of muscles a dynamometer used to test the gripping power of participants making an objective estimate of the strength of the muscles in the upper body. This method had the same validity as that of the whole functional capacity in diabetic populations, with coefficients of 0.70 to 0.85 being most common

    Time frame: baseline pre exam, 6th week of intervention, and 12th week

  3. Chair Stand Test

    In order to evaluate again the strength of the lower limb muscles. The individuals were measured how fast they could stand up from a chair and sit down again and again, which is an indicator of muscle endurance and functional strength. The test has shown really high reliability in diabetic populations with ICC values being around 0.85 to 0.91.

    Time frame: baseline pre exam, 6th week of intervention, and 12th week

  4. The Borg 6-20 Scale

    The Borg 6-20 scale used to measure the rate of perceived exertion. It has a strong relationship with heart rate and oxygen consumption with the range of correlation coefficients between 0.80 and 0.88 for diabetic individuals. The Borg RPE scale in T2DM has a test-retest reliability indicated by the Intraclass Correlation Coefficient (ICC) of about 0.85 to 0.92, which means that people give similar ratings of their exertion consistently across repeated sessions in similar exercise conditions

    Time frame: baseline pre exam, 6th week of intervention, and 12th week

  5. WHOQOL-BREF Questionnaire

    The WHOQOL-BREF is a universal instrument that measures the quality of life in different aspects such as physical health, psychological health, social relationships, and environment. In patients with diabetes, the WHOQOL-BREF reveals a strong internal consistency with Cronbach's alpha values ranging from 0.76 to 0.88

    Time frame: baseline pre exam, 6th week of intervention, and 12th week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jul 2026, 4 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 4 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartEst.
Mar 5, 2026
Primary completionEst.
Jul 17, 2026
CompletionEst.
Sep 22, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07484399
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Mar 5, 2026 (estimated)
Primary completion
Jul 17, 2026 (estimated)
Completion
Sep 22, 2026 (estimated)
Last update
Mar 20, 2026

Study contacts

Imran Amjad, Phd.
Contact
imran.amjad@riphah.edu.pk
03324390125
Sobia Kanwal, tDPT
principal investigator · Riphah International University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion